•Rosacea may double risk for DR progression•WaveFront Dynamics integrates B+L, Wave Eye Care scleral lenses•Side sleepers face higher risk of uneven glaucoma•BostonSight's PROSE treatment linked to Mackie stage, VA gains in NK•Oculis buys out privosegtor’s global rights from Accure•Rosacea may double risk for DR progression•WaveFront Dynamics integrates B+L, Wave Eye Care scleral lenses•Side sleepers face higher risk of uneven glaucoma•BostonSight's PROSE treatment linked to Mackie stage, VA gains in NK•Oculis buys out privosegtor’s global rights from Accure
HEADLINES
FEATURED
Federal agency added Class II classification last week after identifying the potential risk for sterility issues with the OTC product.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
